Overcoming castration resistance in prostate cancer

Related Experiment Video

Updated: May 23, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Che-Kai Tsao1, Alexander C Small, Matthew D Galsky

  • 1Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA.

Current Opinion in Urology
|April 5, 2012
PubMed
Abstract

Insights

New treatments targeting the androgen axis are effective against castration-resistant prostate cancer. Further research will optimize the use of these novel therapies for advanced prostate cancer.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Prostate cancer treatment has advanced with new understanding of the androgen axis signaling pathway.
  • Castration resistance remains a significant challenge in advanced prostate cancer management.

Purpose of the Study:

  • To review mechanisms of castration resistance in prostate cancer.
  • To examine clinical studies of novel therapeutics targeting the androgen-signaling axis.
  • To identify therapeutic opportunities for advanced prostate cancer.

Main Methods:

  • Review of recent advances in understanding androgen axis signaling.
  • Analysis of published and ongoing clinical trials for castration-resistant prostate cancer.
  • Examination of therapeutic strategies for advanced prostate cancer.

Main Results:

  • Secondary hormonal agents like abiraterone and MDV3100 show efficacy in castration-resistant prostate cancer, even post-docetaxel chemotherapy.
  • Phase III clinical trials support the effectiveness of these novel agents.

Conclusions:

  • Novel agents targeting the androgen pathway demonstrate the possibility of overcoming castration resistance.
  • These therapies are transforming treatment paradigms for advanced prostate cancer.
  • Future research will focus on optimal combinations, sequencing, and usage patterns of these novel therapies.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...